Literature DB >> 6759228

Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin.

J S Flier, K L Minaker, L Landsberg, J B Young, J Pallotta, J W Rowe.   

Abstract

The concentration of insulin in plasma is determined by both its rate of secretion and its rate of clearance from the plasma compartment. The effect of marked insulin resistance on insulin clearance in vivo has not been determined in man. We have employed the euglycemic insulin clamp technique to measure insulin sensitivity and insulin clearance in 16 control subjects and in 4 subjects with marked target-cell resistance to insulin. Two insulin-resistant patients had reduced receptor concentration on peripheral mononuclear cells, and two patients had normal receptor number and affinity. During 80-mU/m2/min insulin clamp studies, the clearance rate in each insulin-resistant patient was lower than that in any controls; the mean insulin clearance rate was 511 +/- 74 ml/m2/mon in control subjects and 205 ml/m2/min (P less than 0.001) in insulin-resistant patients. These findings demonstrate an association between marked target-cell resistance to insulin and impaired in vivo insulin clearance, and suggest an important role for receptor-mediated pathways in insulin clearance in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6759228     DOI: 10.2337/diab.31.2.132

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  18 in total

Review 1.  Insulin receptors and the clinician.

Authors:  R Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

Review 2.  Metabolic Abnormalities in Diabetes and Kidney Disease: Role of Uremic Toxins.

Authors:  Laetitia Koppe; Denis Fouque; Christophe O Soulage
Journal:  Curr Diab Rep       Date:  2018-09-08       Impact factor: 4.810

3.  Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance.

Authors:  M C Amato; R Vesco; E Vigneri; A Ciresi; C Giordano
Journal:  J Endocrinol Invest       Date:  2015-08-21       Impact factor: 4.256

4.  The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  C C Lee; C Lorenzo; S M Haffner; L E Wagenknecht; A Festa; M O Goodarzi; D Stefanovski; N C Olson; J M Norris; M J Rewers; A J Hanley
Journal:  Diabetologia       Date:  2012-10-10       Impact factor: 10.122

5.  Chronic pulsatile hyperglycemia reduces insulin secretion and increases accumulation of reactive oxygen species in fetal sheep islets.

Authors:  Alice S Green; Xiaochuan Chen; Antoni R Macko; Miranda J Anderson; Amy C Kelly; Nathaniel J Hart; Ronald M Lynch; Sean W Limesand
Journal:  J Endocrinol       Date:  2011-12-19       Impact factor: 4.286

6.  Insulin degrading enzyme activity and insulin binding of erythrocytes in normal subjects and Type 2 (non-insulin-dependent) diabetic patients.

Authors:  E Standl; H J Kolb
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

Review 7.  Endocrine regulation of bone and energy metabolism in hibernating mammals.

Authors:  Alison H Doherty; Gregory L Florant; Seth W Donahue
Journal:  Integr Comp Biol       Date:  2014-02-19       Impact factor: 3.326

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

9.  Components of metabolic syndrome and 5-year change in insulin clearance - the Insulin Resistance Atherosclerosis Study.

Authors:  C C Lee; C Lorenzo; S M Haffner; L E Wagenknecht; M O Goodarzi; D Stefanovski; J M Norris; M J Rewers; A J Hanley
Journal:  Diabetes Obes Metab       Date:  2013-01-21       Impact factor: 6.577

10.  Effects of aging on glucose-mediated glucose disposal and glucose transport.

Authors:  R I Fink; P Wallace; J M Olefsky
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.